We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current NRIX market cap is 798.44M. The company's latest EPS is USD -2.9441 and P/E is -5.55.
| Quarter End | Feb 2023 | May 2023 | Aug 2023 | Nov 2023 | Feb 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 12.69M | 30.68M | 18.47M | 15.16M | 16.59M |
| Operating Income | -42.95M | -26.77M | -40.01M | -45.33M | -45.22M |
| Net Income | -40.73M | -24.28M | -36.98M | -41.96M | -41.52M |
| Year End 30 November 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 31.12M | 17.82M | 29.75M | 38.63M | 76.99M |
| Operating Income | -22.24M | -64.98M | -117.89M | -183.87M | -155.06M |
| Net Income | -21.7M | -43.24M | -117.19M | -180.36M | -143.95M |
| Quarter End | Feb 2023 | May 2023 | Aug 2023 | Nov 2023 | Feb 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 370.15M | 350.62M | 308.2M | 355.6M | 312.67M |
| Total Liabilities | 96.1M | 90.7M | 74.38M | 155.11M | 143.93M |
| Total Equity | 274.05M | 259.92M | 233.82M | 200.49M | 168.75M |
| Year End 30 November 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 44.05M | 396.34M | 476.77M | 416.76M | 355.6M |
| Total Liabilities | 53.57M | 106.07M | 134.47M | 113.06M | 155.11M |
| Total Equity | -57.71M | 290.27M | 342.3M | 303.7M | 200.49M |
| Quarter End | Feb 2023 | May 2023 | Aug 2023 | Nov 2023 | Feb 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -48.45M | -66.92M | -108.05M | -81.37M | -41.95M |
| Investing | 16.07M | 59.9M | 82.67M | 68.3M | 35.51M |
| Financing | 1.48M | 1.51M | 3.21M | 3.22M | 1.62M |
| Year End 30 November 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 601k | -80k | -84.37M | -159.81M | -81.37M |
| Investing | 8.5M | -254.4M | -108.25M | 27.2M | 68.3M |
| Financing | 126k | 339.02M | 153.88M | 117.19M | 3.22M |
| Market Cap | 798.44M |
| Price to Earnings Ratio | -5.55 |
| Price to Sales Ratio | 10.37 |
| Price to Cash Ratio | 14.62 |
| Price to Book Ratio | 3.98 |
| Dividend Yield | - |
| Shares Outstanding | 48.89M |
| Average Volume (1 week) | 788.58k |
| Average Volume (1 Month) | 933.05k |
| 52 Week Change | 43.62% |
| 52 Week High | 18.12 |
| 52 Week Low | 4.22 |
| Spread (Intraday) | 2.3 (13.69%) |
| Company Name | Nurix Therapeutics Inc |
| Address |
3500 s dupont hwy dover, delaware 19901 |
| Website | https://www.nurixtx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
